Home » Apotex Launches First Generic Version of Merck’s Nasonex Spray
Apotex Launches First Generic Version of Merck’s Nasonex Spray
Apotex has launched the first generic version of Merck’s once-daily Nasonex spray, the drugmaker announced last week.
Nasonex raked in roughly $955.5 million in sales in a 12-month period that ended in January, according to IMS Health.
In June 2013, the Federal Circuit upheld a decision that Apotex had not infringed patents covering the drug.
Upcoming Events
-
07May
-
14May
-
30May